Terms: = Breast cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS AND Prognosis
4 results:
1. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M; van der Noort V; Kleijn M; Glas A; Mandjes I; Kleiterp S; Hilbers FS; Kruger DT; Bins AD; de Jong PC; Schiphorst PPJBM; van Dalen T; Flameling B; Rietbroek RC; Beeker A; van den Heiligenberg SM; Bakker SD; Wymenga ANM; Oving IM; Bijlsma RM; van Diest PJ; Vermorken JB; van Tinteren H; Linn SC
Breast Cancer Res Treat; 2022 Jul; 194(2):265-278. PubMed ID: 35587322
[TBL] [Abstract] [Full Text] [Related]
2. Knockdown of nuclear receptor binding SET domain-containing protein 1 (nsd1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.
Chen Y; Li X; Xu J; Xiao H; Tang C; Liang W; Zhu X; Fang Y; Wang H; Shi J
Bioengineered; 2022 Feb; 13(2):3526-3536. PubMed ID: 35200072
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A; Yu NY; Iftimi A; Tobin NP; van 't Veer L; Nordenskjöld B; Benz CC; Fornander T; Perez-Tenorio G; Stål O; Esserman LJ; Yau C; Lindström LS
Int J Cancer; 2022 Jun; 150(12):2072-2082. PubMed ID: 35179782
[TBL] [Abstract] [Full Text] [Related]
4. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
van 't Veer LJ; Yau C; Yu NY; Benz CC; Nordenskjöld B; Fornander T; Stål O; Esserman LJ; Lindström LS
Breast Cancer Res Treat; 2017 Nov; 166(2):593-601. PubMed ID: 28776283
[TBL] [Abstract] [Full Text] [Related]
